GlassScriptPhysician profile
Timothy J Hardy
NPI 1487662748
$2,721.74
in general payments reported to CMS, 2019-2025
30 companies · $403 in 2025
The $403 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $146 · 2021: $305 · 2022: $362 · 2023: $588 · 2024: $675 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.15 |
| Education | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.10 | 2019-2025 | |
| Caldera Medical, INC | $253.73 | 2023-2024 | Desara |
| Astellas Pharma US INC | $225.92 | 2019-2024 | Veozah |
| Sumitomo Pharma America, INC. | $214.20 | 2023-2025 | Myfembree, Gemtesa |
| Minerva Surgical, INC | $137.02 | 2019-2025 | |
| Pfizer INC. | $113.98 | 2023-2024 | |
| Myovant Sciences INC. | $96.06 | 2021-2022 | |
| Organon LLC | $81.78 | 2021-2023 | Nexplanon |
| Lilly USA, LLC | $77.37 | 2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $66.47 | 2021 | |
| Merck Sharp & Dohme LLC | $65.95 | 2019-2021 | |
| Exeltis, USA INC. | $51.55 | 2021-2025 | Slynd |
| Axonics, INC. | $39.23 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.01 | 2019 | |
| Therapeuticsmd, INC. | $37.22 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $36.35 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $22.68 | 2023 | Vivjoa |
| Daiichi Sankyo INC. | $22.51 | 2022 | |
| Fidia Pharma USA INC. | $19.63 | 2022 | |
| Allergan, INC. | $19.11 | 2019 | |
| Amgen INC. | $18.42 | 2024 | Prolia, Evenity |
| Amag Pharmaceuticals, INC. | $17.33 | 2020 | |
| Mayne Pharma Commercial LLC | $16.17 | 2025 | |
| Scynexis, INC. | $14.74 | 2022 | |
| Viiv Healthcare Company | $14.28 | 2023 | Apretude |
| Vertical Pharmaceuticals, LLC | $13.38 | 2020 | |
| Millicent US INC | $13.35 | 2024 | |
| Meditrina | $12.57 | 2024 | |
| Alydia Health | $4.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.